Global Biopharmaceuticals Market - Segmented by Type of Products and Applications - Growth, Trends and Forecasts (2018 - 2023)

  • ID: 4472662
  • Report
  • Region: Global
  • 105 pages
  • Mordor Intelligence
1 of 4

FEATURED COMPANIES

  • ABBVIE
  • AMGEN
  • BRISTOL – MYERS SQUIBB
  • ELI LILY & CO
  • GLAXOSMITHKLINE PLC
  • JOHNSON & JOHNSON
  • MORE
The global Biopharmaceuticals market has been estimated to reach USD 341.16 billion in 2023. The market is expected to register a CAGR of 8.5% during the forecast period 2018 to 2023. North America dominates the market due to the increasing technological advancements.

Increasing acceptance for biopharmaceuticals and huge market demand

Opportunities in biopharmaceuticals have been increasing over the past decade. The efficacy and the safety of the drugs are some of the key products features that drive the market growth. There have been biopharmaceutical products that are improving the quality of life and reducing the death rates in patients with HIV/AIDs, Cancer, Cystic fibrosis, rheumatoid arthritis. Biopharmaceuticals have reduced the number of deaths caused due to cancer and HIV/AIDS in the last decade. The efficacy of the drugs and the safety has increased the acceptance for biopharmaceuticals.

High-end manufacturing requirements

Unlike conventional pharmaceuticals, biopharmaceuticals are manufactured using living biological systems. Due to this, the biopharmaceutical manufacturing requires specialized equipment and devices like incubators that can support these biological systems. The cost of these devices and equipment is high as compared to regular manufacturing equipment. Along with this, most of the biopharmaceuticals require custom built manufacturing equipment and highly specialized personnel to operate them. Due to these high-end manufacturing requirements, the resources and time required to setup a biopharmaceutical manufacturing facility is very high which makes scaling really tough. So, these factors are acting as a restraint for Biopharmaceuticals market.

North America to Dominate the Market

The Biopharmaceuticals market is segmented by type of treatment and geography. By geography it is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa and South America.

North America dominates the Biopharmaceuticals market due to the increasing technological advancements and high investment & funding to support development of Biopharmaceuticals. Asia-Pacific is also expected to propel the Biopharmaceuticals market owing to factors, such as increasing accessibility to healthcare facilities in the region, and increasing economic growth.

Key developments in the market
  • In January, 2018, GE Healthcare’s Flex Factory single-use bio manufacturing platform has been selected by Clover Biopharmaceuticals, a Chinese developer of biologics, for its new facility located in Changxing, Zhejiang.
  • In January, 2018, Sandoz, a Novartis division and the global leader in biosimilars, announced a global partnership with Asia's premier biopharmaceuticals company, Biocon, to develop, manufacture and commercialize multiple biosimilars in immunology and oncology for patients worldwide.
Major key players: ABBVIE, AMGEN, BRISTOL - MYERS SQUIBB, ELI LILY & CO, JOHNSON & JOHNSON, MERCK & CO. INC, GLAXOSMITHKLINE PLC, ROCHE, PFIZER and NOVARTIS AG etc.

Reasons to purchase this report
  • Market analysis for the Global Biopharmaceuticals Market, with region-specific assessments and competition analysis on a global and regional scale.
  • Analyzing various perspectives of the company with the help of Porter’s five forces analysis
  • The treatment type that is expected to dominate the market
  • Regions that are expected to witness fastest growth during the forecast period
  • Identify the latest developments, market shares and strategies employed by the major market players.
  • 3 months analyst support along with the Market Estimate sheet in excel.
Customization of the Report

This report can be customized to meet your requirements. Please contact us for more information.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • ABBVIE
  • AMGEN
  • BRISTOL – MYERS SQUIBB
  • ELI LILY & CO
  • GLAXOSMITHKLINE PLC
  • JOHNSON & JOHNSON
  • MORE
TABLE OF CONTENTS
1. INTRODUCTION
1.1 MARKET DEFINITION

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. KEY INFERENCES

5. MARKET OVERVIEW
5.1 CURRENT MARKET SCENARIO
5.2 PORTER’S FIVE FORCES
5.2.1 BARGAINING POWER OF SUPPLIERS
5.2.2 BARGAINING POWER OF CONSUMERS
5.2.3 THREATS OF NEW ENTRANTS
5.2.4 THREAT OF SUBSTITUTE PRODUCT AND SERVICES
5.2.5 COMPETITIVE RIVALRY WITHIN THE INDUSTRY

6. DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES ANALYSIS (DROC)
6.1 MARKET DRIVERS
6.1.1 INCREASING ACCEPTANCE FOR BIOPHARMACEUTICALS
6.1.2 HUGE MARKET DEMAND
6.2 MARKET RESTRAINTS
6.2.1 HIGH-END MANUFACTURING REQUIREMENTS
6.3 OPPORTUNITIES
6.4 KEY CHALLENGES

7. Market Segmentation
7.1 GLOBAL BIOPHARMACEUTICALS MARKET, BY PRODUCT/TYPE
7.2 MONOCLONAL ANTIBODIES
7.2.1 ANTI-CANCER MONOCLONAL ANTIBODIES
7.2.2 ANTI-INFLAMMATORY MONOCLONAL ANTIBODIES
7.2.3 OTHER MONOCLONAL ANTIBODIES
7.3 RECOMBINANT GROWTH FACTORS
7.3.1 ERYTHROPOIETIN
7.3.2 GRANULOCYTE COLONY STIMULATING FACTOR
7.4 PURIFIED PROTEINS
7.4.1 LEUKEMIA INHIBITORY FACTOR (LIF)
7.4.2 P53 PROTEIN
7.4.3 P38 PROTEIN
7.5 RECOMBINANT PROTEINS
7.5.1 SERUM ALBUMIN
7.5.2 AMYLOID PROTEIN
7.5.3 DEFENSIN
7.5.4 CYCLASE
7.5.5 CASPASE
7.5.6 CATHEPSIN
7.6 RECOMBINANT HORMONES
7.6.1 RECOMBINANT HUMAN GROWTH HORMONE (HGH)
7.6.2 INSULIN
7.7 SYNTHETIC IMMUNOMODULATORS
7.8 VACCINES
7.8.1 RECOMBINANT VACCINES
7.8.1.1 CANCER VACCINES
7.8.1.2 MALARIA VACCINES
7.8.1.3 EBOLA VACCINE
7.8.1.4 HEPATITIS-B VACCINE
7.8.1.5 TETANUS VACCINE
7.8.1.6 DIPTHERIA VACCINE
7.8.1.7 CHOLERA VACCINE
7.8.2 CONVENTIONAL VACCINES
7.8.2.1 POLIO VACCINE
7.8.2.2 POX VACCINE
7.9 RECOMBINANT ENZYMES
7.9.1 ENTEROKINASE
7.9.2 TRANSFERRIN
7.10 OTHERS
7.10.1 BLOOD FACTORS
7.10.2 OTHERS
7.11 BY GEOGRAPHY
7.11.1 NORTH AMERICA
7.11.1.1 US
7.11.1.2 CANADA
7.11.1.3 MEXICO
7.11.2 EUROPE
7.11.2.1 FRANCE
7.11.2.2 UK
7.11.2.3 GERMANY
7.11.2.4 ITALY
7.11.2.5 SPAIN
7.11.2.6 REST OF EUROPE
7.11.3 ASIA-PACIFIC
7.11.3.1 INDIA
7.11.3.2 CHINA
7.11.3.3 JAPAN
7.11.3.4 AUSTRALIA
7.11.3.5 SOUTH KOREA
7.11.3.6 REST OF APAC
7.11.4 MIDDLE EAST AND AFRICA
7.11.4.1 GCC
7.11.4.2 SOUTH AFRICA
7.11.4.3 REST OF MIDDLE EAST AND AFRICA
7.11.5 SOUTH AMERICA
7.11.5.1 BRAZIL
7.11.5.2 ARGENTINA
7.11.5.3 REST OF SOUTH AMERICA

8. COMPETITIVE LANDSCAPE
8.1 MERGERS AND ACQUISITIONS
8.2 AGREEMENTS, COLLABORATIONS AND PARTNERSHIPS
8.3 NEW PRODUCT LAUNCHES

9. KEY PLAYERS
9.1 ABBVIE
9.2 AMGEN
9.3 BRISTOL – MYERS SQUIBB
9.4 ELI LILY & CO
9.5 JOHNSON & JOHNSON
9.6 MERCK & CO. INC
9.7 NOVARTIS AG
9.8 PFIZER
9.9 GLAXOSMITHKLINE PLC
9.10 ROCHE HOLDING
9.11 OTHERS

10. FUTURE OUTLOOK OF THE MARKET
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • ABBVIE
  • AMGEN
  • BRISTOL – MYERS SQUIBB
  • ELI LILY & CO
  • JOHNSON & JOHNSON
  • MERCK & CO. INC
  • NOVARTIS AG
  • PFIZER
  • GLAXOSMITHKLINE PLC
  • ROCHE HOLDING
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll